艾昆纬-加拿大心理健康障碍的药物治疗（英）

Medication Treatments for Mental Health Disorders in CanadaAn independent IQVIA report on drug utilization data, 2019–2023 2 | Medication Treatments for Mental Health Disorders in Canada IntroductionAccording to Health Canada, mental illness is characterized by changes in an individual’s thinking, mood, or behaviour, and is usually associated with significant distress or impaired functioning in social, occupational, or other activities. By all accounts, mental illnesses have a significant impact on the health of Canadians, as well as on the Canadian economy, including our health and social services systems.Mental illness indirectly affects all Canadians at some point, either through their own experience or that of a family member, friend, or colleague. In any given year, 1 in 5 Canadians experience a mental illness, and by the time Canadians reach the age of 40, 1 in 2 Canadians are experiencing – or have experienced – a mental illness. The economic cost of mental illness to Canada’s health and social service systems was estimated at $79.9 billion in 20211. This includes health care costs, lost productivity, and reductions in health-related quality of life.The CIHI report, “Repeat Hospital Stays for Mental Health and Substance Use”2 reveals that in Canada, 1 in 7 patients with a mental illness requires repeated hospitalization. Depending on the availability of mental health care in the various health regions, this is at best 1 in 12 patients, and at worst 1 in 4.While medication utilization statistics were the primary focus of this report, other effective treatments and services are also available, including psychotherapy and crisis lines, virtual services/telemedicine, community supports, alternative medicine, prevention and promotion interventions, and workplace supports. However, the increased demand for these services in the post-pandemic era and the shortage of specialized professionals has meant that psychotropic medications are often used to achieve positive clinical outcomes from psychosis to depression. In 2023, the number of clinical trials for depression worldwide decreased by 25% compared to 2022, with 40% of these trials initiated with psychedelics.3Our focus at IQVIA is to help optimize health by bringing data and fact-based insights forward to better inform decision-makers in this critical area, with the utmost respect for privacy and data security. The statistics and analysis featured in this report were sourced from the IQVIA Health Insights Dashboard, as part of a collaboration with the IQVIA Advisory Council for the Advancement of Health, a group of Quebec opinion leaders from various health sectors. A true public-utility analysis tool, based on fully anonymized data, the dashboard is used to analyze drug usage in select treatment classes and is designed to answer three basic questions: how many prescriptions, for how many users, and by which prescriber medical specialties. Refer to page 6 for the limitations associated with